Osimertinib which was originally developed for tumors that developed tolerance to first- or second-generation EGFR-TKIs, targeting T790M, showed a dramatic response in T790M-positive NSCLC patients13,26. This evidence concerns the gene EGFR and non-small cell lung carcinoma.